Selected research
Industry Research
Interleukin 1 (IL1) Industry Research Report 2026
Market perspective
The global Interleukin 1 (IL1) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Interleukin 1 (IL1) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Interleukin 1 (IL1) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Interleukin 1 (IL1) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Interleukin 1 (IL1) include Novartis AG, AbbVie Inc, XBiotech Inc, TWi Biotechnology Inc, Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals Inc, R Pharm, Peptinov SAS and Orphit SAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Interleukin 1 (IL1) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Interleukin 1 (IL1) Market by Company
Novartis AG
AbbVie Inc
XBiotech Inc
TWi Biotechnology Inc
Swedish Orphan Biovitrum AB
Regeneron Pharmaceuticals Inc
R Pharm
Peptinov SAS
Orphit SAS
Optimum Therapeutics LLC
Opsona Therapeutics Ltd
Omnitura Therapeutics Inc
Immune Response BioPharma Inc
Exicure Inc
Cell Medica Ltd
Apexigen Inc
Anacor Pharmaceuticals Inc
Interleukin 1 (IL1) Segment by Type
APX-002
Diacerein CR
Canakinumab
IR-1000
Others
Interleukin 1 (IL1) Segment by Application
Fallopian Tube Cancer
Esophageal Cancer
Bechcer Disease
Bladder Cancer
Others
Interleukin 1 (IL1) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 1 (IL1) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin 1 (IL1) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 1 (IL1).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Interleukin 1 (IL1) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Interleukin 1 (IL1) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Interleukin 1 (IL1) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- APX-002
- Diacerein CR
- Canakinumab
- IR-1000
- Others
Applications
- Fallopian Tube Cancer
- Esophageal Cancer
- Bechcer Disease
- Bladder Cancer
- Others
Companies covered
- Novartis AG
- AbbVie Inc
- XBiotech Inc
- TWi Biotechnology Inc
- Swedish Orphan Biovitrum AB
- Regeneron Pharmaceuticals Inc
- R Pharm
- Peptinov SAS
- Orphit SAS
- Optimum Therapeutics LLC
- Opsona Therapeutics Ltd
- Omnitura Therapeutics Inc
- Immune Response BioPharma Inc
- Exicure Inc
- Cell Medica Ltd
- Apexigen Inc
- Anacor Pharmaceuticals Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Interleukin 1 (IL1) Market Size (2021-2032)
- 2.2.2 Global Interleukin 1 (IL1) Sales (2021-2032)
- 2.2.3 Global Interleukin 1 (IL1) Market Average Price (2021-2032)
- 2.3 Interleukin 1 (IL1) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 APX-002
- 2.3.3 Diacerein CR
- 2.3.4 Canakinumab
- 2.3.5 IR-1000
- 2.3.6 Others
- 2.4 Interleukin 1 (IL1) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Fallopian Tube Cancer
- 2.4.3 Esophageal Cancer
- 2.4.4 Bechcer Disease
- 2.4.5 Bladder Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Interleukin 1 (IL1) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Interleukin 1 (IL1) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Interleukin 1 (IL1) Revenue of Manufacturers (2021-2026)
- 3.4 Global Interleukin 1 (IL1) Average Price by Manufacturers (2021-2026)
- 3.5 Global Interleukin 1 (IL1) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Interleukin 1 (IL1), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Interleukin 1 (IL1), Product Type & Application
- 3.8 Global Manufacturers of Interleukin 1 (IL1), Established Date
- 3.9 Global Interleukin 1 (IL1) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Interleukin 1 (IL1) Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 AbbVie Inc
- 4.2.1 AbbVie Inc Company Information
- 4.2.2 AbbVie Inc Business Overview
- 4.2.3 AbbVie Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AbbVie Inc Interleukin 1 (IL1) Product Portfolio
- 4.2.5 AbbVie Inc Recent Developments
- 4.3 XBiotech Inc
- 4.3.1 XBiotech Inc Company Information
- 4.3.2 XBiotech Inc Business Overview
- 4.3.3 XBiotech Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 XBiotech Inc Interleukin 1 (IL1) Product Portfolio
- 4.3.5 XBiotech Inc Recent Developments
- 4.4 TWi Biotechnology Inc
- 4.4.1 TWi Biotechnology Inc Company Information
- 4.4.2 TWi Biotechnology Inc Business Overview
- 4.4.3 TWi Biotechnology Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 TWi Biotechnology Inc Interleukin 1 (IL1) Product Portfolio
- 4.4.5 TWi Biotechnology Inc Recent Developments
- 4.5 Swedish Orphan Biovitrum AB
- 4.5.1 Swedish Orphan Biovitrum AB Company Information
- 4.5.2 Swedish Orphan Biovitrum AB Business Overview
- 4.5.3 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Product Portfolio
- 4.5.5 Swedish Orphan Biovitrum AB Recent Developments
- 4.6 Regeneron Pharmaceuticals Inc
- 4.6.1 Regeneron Pharmaceuticals Inc Company Information
- 4.6.2 Regeneron Pharmaceuticals Inc Business Overview
- 4.6.3 Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio
- 4.6.5 Regeneron Pharmaceuticals Inc Recent Developments
- 4.7 R Pharm
- 4.7.1 R Pharm Company Information
- 4.7.2 R Pharm Business Overview
- 4.7.3 R Pharm Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 R Pharm Interleukin 1 (IL1) Product Portfolio
- 4.7.5 R Pharm Recent Developments
- 4.8 Peptinov SAS
- 4.8.1 Peptinov SAS Company Information
- 4.8.2 Peptinov SAS Business Overview
- 4.8.3 Peptinov SAS Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Peptinov SAS Interleukin 1 (IL1) Product Portfolio
- 4.8.5 Peptinov SAS Recent Developments
- 4.9 Orphit SAS
- 4.9.1 Orphit SAS Company Information
- 4.9.2 Orphit SAS Business Overview
- 4.9.3 Orphit SAS Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orphit SAS Interleukin 1 (IL1) Product Portfolio
- 4.9.5 Orphit SAS Recent Developments
- 4.10 Optimum Therapeutics LLC
- 4.10.1 Optimum Therapeutics LLC Company Information
- 4.10.2 Optimum Therapeutics LLC Business Overview
- 4.10.3 Optimum Therapeutics LLC Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Optimum Therapeutics LLC Interleukin 1 (IL1) Product Portfolio
- 4.10.5 Optimum Therapeutics LLC Recent Developments
- 4.11 Opsona Therapeutics Ltd
- 4.11.1 Opsona Therapeutics Ltd Company Information
- 4.11.2 Opsona Therapeutics Ltd Business Overview
- 4.11.3 Opsona Therapeutics Ltd Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Opsona Therapeutics Ltd Interleukin 1 (IL1) Product Portfolio
- 4.11.5 Opsona Therapeutics Ltd Recent Developments
- 4.12 Omnitura Therapeutics Inc
- 4.12.1 Omnitura Therapeutics Inc Company Information
- 4.12.2 Omnitura Therapeutics Inc Business Overview
- 4.12.3 Omnitura Therapeutics Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Omnitura Therapeutics Inc Interleukin 1 (IL1) Product Portfolio
- 4.12.5 Omnitura Therapeutics Inc Recent Developments
- 4.13 Immune Response BioPharma Inc
- 4.13.1 Immune Response BioPharma Inc Company Information
- 4.13.2 Immune Response BioPharma Inc Business Overview
- 4.13.3 Immune Response BioPharma Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Immune Response BioPharma Inc Interleukin 1 (IL1) Product Portfolio
- 4.13.5 Immune Response BioPharma Inc Recent Developments
- 4.14 Exicure Inc
- 4.14.1 Exicure Inc Company Information
- 4.14.2 Exicure Inc Business Overview
- 4.14.3 Exicure Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Exicure Inc Interleukin 1 (IL1) Product Portfolio
- 4.14.5 Exicure Inc Recent Developments
- 4.15 Cell Medica Ltd
- 4.15.1 Cell Medica Ltd Company Information
- 4.15.2 Cell Medica Ltd Business Overview
- 4.15.3 Cell Medica Ltd Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Cell Medica Ltd Interleukin 1 (IL1) Product Portfolio
- 4.15.5 Cell Medica Ltd Recent Developments
- 4.16 Apexigen Inc
- 4.16.1 Apexigen Inc Company Information
- 4.16.2 Apexigen Inc Business Overview
- 4.16.3 Apexigen Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Apexigen Inc Interleukin 1 (IL1) Product Portfolio
- 4.16.5 Apexigen Inc Recent Developments
- 4.17 Anacor Pharmaceuticals Inc
- 4.17.1 Anacor Pharmaceuticals Inc Company Information
- 4.17.2 Anacor Pharmaceuticals Inc Business Overview
- 4.17.3 Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio
- 4.17.5 Anacor Pharmaceuticals Inc Recent Developments
5 Global Interleukin 1 (IL1) Market Scenario by Region
- 5.1 Global Interleukin 1 (IL1) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Interleukin 1 (IL1) Sales by Region: 2021-2032
- 5.2.1 Global Interleukin 1 (IL1) Sales by Region: 2021-2026
- 5.2.2 Global Interleukin 1 (IL1) Sales by Region: 2027-2032
- 5.3 Global Interleukin 1 (IL1) Revenue by Region: 2021-2032
- 5.3.1 Global Interleukin 1 (IL1) Revenue by Region: 2021-2026
- 5.3.2 Global Interleukin 1 (IL1) Revenue by Region: 2027-2032
- 5.4 North America Interleukin 1 (IL1) Market Facts & Figures by Country
- 5.4.1 North America Interleukin 1 (IL1) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Interleukin 1 (IL1) Sales by Country (2021-2032)
- 5.4.3 North America Interleukin 1 (IL1) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Interleukin 1 (IL1) Market Facts & Figures by Country
- 5.5.1 Europe Interleukin 1 (IL1) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Interleukin 1 (IL1) Sales by Country (2021-2032)
- 5.5.3 Europe Interleukin 1 (IL1) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Interleukin 1 (IL1) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Interleukin 1 (IL1) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Interleukin 1 (IL1) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Interleukin 1 (IL1) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Interleukin 1 (IL1) Market Facts & Figures by Country
- 5.7.1 South America Interleukin 1 (IL1) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Interleukin 1 (IL1) Sales by Country (2021-2032)
- 5.7.3 South America Interleukin 1 (IL1) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Interleukin 1 (IL1) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Interleukin 1 (IL1) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Interleukin 1 (IL1) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Interleukin 1 (IL1) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Interleukin 1 (IL1) Sales by Type (2021-2032)
- 6.1.1 Global Interleukin 1 (IL1) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Interleukin 1 (IL1) Sales Market Share by Type (2021-2032)
- 6.2 Global Interleukin 1 (IL1) Revenue by Type (2021-2032)
- 6.2.1 Global Interleukin 1 (IL1) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Interleukin 1 (IL1) Revenue Market Share by Type (2021-2032)
- 6.3 Global Interleukin 1 (IL1) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Interleukin 1 (IL1) Sales by Application (2021-2032)
- 7.1.1 Global Interleukin 1 (IL1) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Interleukin 1 (IL1) Sales Market Share by Application (2021-2032)
- 7.2 Global Interleukin 1 (IL1) Revenue by Application (2021-2032)
- 7.2.1 Global Interleukin 1 (IL1) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Interleukin 1 (IL1) Revenue Market Share by Application (2021-2032)
- 7.3 Global Interleukin 1 (IL1) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Interleukin 1 (IL1) Value Chain Analysis
- 8.1.1 Interleukin 1 (IL1) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Interleukin 1 (IL1) Production Mode & Process
- 8.2 Interleukin 1 (IL1) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Interleukin 1 (IL1) Distributors
- 8.2.3 Interleukin 1 (IL1) Customers
9 Global Interleukin 1 (IL1) Analyzing Market Dynamics
- 9.1 Interleukin 1 (IL1) Industry Trends
- 9.2 Interleukin 1 (IL1) Industry Drivers
- 9.3 Interleukin 1 (IL1) Industry Opportunities and Challenges
- 9.4 Interleukin 1 (IL1) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst